Compare Alcon AG (ALC) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Procter & Gamble Co — how do they compare? Alcon AG trades at $74.19 (market cap $35.19B), while Procter & Gamble Co trades at $144.67 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 9.7× Alcon AG's market cap, and Procter & Gamble Co pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| ALC | PG | |
|---|---|---|
Market Cap | $35.19B | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $90.12 | $167.18 |
52-Week Low | $62.02 | $138.10 |
Enterprise Value | $39.03B | $366.23B |
Dividend Yield | 0.49% | 2.97% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $71.81, up 3.26% today, with a bullish technical signal supported by moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.84, beating estimates, and raised its profit guidance on August 11, 2026, citing strong product launches. Revenue grew to $10.4B in 2025, though net income margin dipped to 9.42%. Valuation ratios include a P/E of 43 and P/S of 3.34, reflecting premium pricing.
Outlook is positive with analyst consensus at 54% buy ratings and a 27.8% upside target, but risks include margin pressure and high debt. The stock offers growth potential from innovation but faces competitive and macroeconomic headwinds.
Procter & Gamble (PG) trades at $146.38, up 0.42% on the day, with a bearish technical signal but strong fundamentals including a net income margin of 18.44% and consistent earnings beats. The company maintains robust cash flow from operations of $17.82B in 2025 and a dividend track record, with a recent partnership with the WNBA signaling strategic brand expansion. Valuation ratios like P/E of 22.12 and P/S of 4.08 reflect a premium to peers amid modest revenue growth.
PG offers stability with high profitability and dividend reliability, but premium valuation and soft demand outlook pose near-term risks. Analyst consensus is bullish with a $161.20 price target, though technical indicators suggest caution. Key risks include economic sensitivity and competitive pressures, while institutional holdings show mixed sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
